Clinical Trial: Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC

U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07765836) titled 'Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC' on Aug. 10.

Brief Summary: This is a single arm, open-label, non-randomized multi-institution phase II trial of a Fc enhanced CTLA4 antibody, vilastobart, in combination with PD-1 antibody, retifanlimab, in patients with BRCA1, BRCA2 or PALB2 deficient pancreatic cancer (PC).

Study Start Date: Jan., 2027

Study Type: INTERVENTIONAL

Condition: Pancreatic Cancer Metastatic

Intervention: DRUG: vilastobart (XTX101)

100mg administered once every 6 weeks (Day 1 of every 6-week cycle) by intravenous infusion (IV) over about 90-140 minutes. This will continue for up to 4 6-week c...